Literature DB >> 7795399

Contact transscleral cyclophotocoagulation with diode laser in refractory glaucoma.

R Brancato1, R G Carassa, P Bettin, M Fiori, G Trabucchi.   

Abstract

OBJECTIVE: To evaluate the clinical effectiveness of contact transscleral cyclophotocoagulation (CTCP) with diode laser. DESIGN AND PATIENTS: Forty-eight seeing eyes and 20 blind and painful eyes of 68 patients suffering from refractory glaucoma were treated using a diode laser (EOS3000, Laser Science) coupled with a 400-microns optic fiber ending in a 3-mm focusing tip. Sixteen to twenty 3.9-J (2.6 W x 1.5 to 2.5 s) laser spots were placed over 360 degrees, 1.5 mm from the corneolimbal junction.
RESULTS: In the seeing-eye group, the follow-up was 20.7 +/- 8.14 months, pre- and posttreatment IOPs were 37.1 +/- 11.27 and 19.5 +/- 8.73 mmHg respectively (p < 0.0001), and success (IOP > 2 and < or = 21 mmHg) was 70.8%. No significant visual acuity change was found in the successful eyes, whereas a significant visual acuity reduction was found in the unsuccessful cases (p = 0.03). In the blind-eye group, the follow-up was 20.5 +/- 8.54 months, pre- and post-treatment IOPs were 50.7 +/- 15.05 and 20.6 +/- 13.99 mmHg respectively (p < 0.0001), and success (remission of pain) was 100%. As for complications, one seeing eye developed a spontaneously-resolved vitreous hemorrhage and one seeing and one blind eye became hypotonic, though no phthysis was observed. No conjunctival or lens damage was detected, and no scleral thinning was revealed by ultrasound biomicroscopy. No case of sympathetic ophthalmia was found.
CONCLUSIONS: Diode laser can be successfully employed for CTCP in refractory glaucoma.

Entities:  

Mesh:

Year:  1995        PMID: 7795399     DOI: 10.1177/112067219500500106

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  22 in total

1.  Real-time imaging of transscleral diode laser cyclophotocoagulation by optical coherence tomography.

Authors:  H Hoerauf; M Müller; G Hüttmann; C Winter; T Schlote
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

2.  Controlled cyclophotocoagulation with the 940 nm laser for primary open angle glaucoma in African eyes.

Authors:  Paul-Rolf Preussner; Faustin Ngounou; Gabriel Kouogan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

Review 3.  [Controlled cyclophotocoagulation (COCO) : What needs to be considered?]

Authors:  P-R Preußner
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

4.  "Cyclodiode": results of a standard protocol.

Authors:  A F Spencer; S A Vernon
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

5.  Cyclodiode laser therapy for painful, blind glaucomatous eyes.

Authors:  K R Martin; D C Broadway
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

6.  Real-time control for transscleral cyclophotocoagulation.

Authors:  P R Preussner; N Boos; K Fassbender; O Schwenn; N Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-12       Impact factor: 3.117

7.  Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma.

Authors:  M E Iliev; S Gerber
Journal:  Br J Ophthalmol       Date:  2007-05-10       Impact factor: 4.638

8.  A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma.

Authors:  C C Murphy; C A M Burnett; P G D Spry; D C Broadway; J P Diamond
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

9.  Controlled Cyclophotocoagulation with diode laser in refractory glaucoma and long term follow up at King Abdulaziz University Hospital, Riyadh.

Authors:  Essam A Osman; Abdulrahman Al-Muammar; Ahmed Mousa; Hani Al-Mezaine; Saleh A Al-Obeidan
Journal:  Saudi J Ophthalmol       Date:  2010-01-07

10.  Cyclophotocoagulation and cyclocryocoagulation as primary surgical procedures for open-angle glaucoma.

Authors:  Isabel Gorsler; Hagen Thieme; Christian Meltendorf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-04       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.